Diclazuril
PreclinicalSmall molecule
Johnson & JohnsonDiclazuril is one of 7 small molecule programs targeting Cryptosporidiosis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Cryptosporidiosis
#DrugCompanyPhaseTrials
1Alinia
RRomark Laboratories L.C.
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cryptosporidium Parvum Oocysts (ABO809)
NovartisPhase 2
EDI048
NovartisPhase 2
Spiramycin
RRhone-Poulenc Rorer
Preclinical
Diclazuril
Johnson & JohnsonPreclinical
Interleukin-12
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diclazuril. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company